326030 — SK Biopharmaceuticals Co Share News
0.000.00%
Last trade - 00:00- KR₩6tn
- KR₩6tn
- KR₩707bn
Brief: Sk Biopharmaceuticals Wins 31 Billion Won Order
Brief: Sk Biopharmaceuticals Co Wins 21 Billion Won Order
Brief: SK Biopharmaceuticals Q3 Operating Loss 9 Billion Won
Brief: Sk Biopharmaceuticals Wins 61.5 Billion Won Order
Brief: SK Biopharmaceuticals Co Signs $17 Million Deal With SK Life Science Inc To Sell Cenobamate In U.S.
Brief: SK Biopharmaceuticals, Eurofarma Enter Into Licensing Agreement For Cenobamate In Latin America
Brief: SK Biopharmaceuticals Says To Acquire 177 Billion Won Worth Of Shares In Ignis Therapeutics
WHO expects decision on emergency listing for Chinese vaccines soon (updated)
Vaccine developer SK Bioscience to raise $1.3 bln in S.Korea's largest IPO since 2017 (updated)
Brief: SK Holdings Says Sold Shares In SK Biopharmaceuticals In Block Deal Worth $991 Mln
WHO chief says drug firms should share vaccine-making capacity (updated)
Indebted South Korea retail stock buyers face reality check as short selling to resume
South Korea's IPO market poised for record year on booming retail demand
South Korea's IPO market poised for record year on booming retail demand
Italy's healthcare group Angelini buys Swiss-based Arvelle in $1 bln deal
Vaccine developer SK Bioscience targets IPO in first half of 2021 (updated)
Signed An Agreement With Lifesci Venture Partners To Collaborate On Open Innovation Through A Fund
Brief: SK Biopharmaceuticals says Co And Ono Pharmaceutical Enter Licensing Agreement For Cenobamate In Japan
Brief: Sk Biopharmaceuticals Signs Technology Transfer Agreement Worth $505 Mln With Ono Pharmaceutical Co